AGP Limited: Clarification on Azomax Counterfeit Alert
Summary
AGP clarifies that the counterfeit Azomax alert does not pertain to its genuine product, ensuring no impact on operations or compliance.
Kind of disclosure: Regulatory/Legal
Read the original filingKey facts
- Counterfeit Azomax alert issued
- Prompt Alert No. 97/2026
- Annual sales of Azomax
- Rs 5B
- No impact on AGP's operations
- GMP compliant manufacturing
- Regulatory authorities involved
- Directorate of Drugs Control, DRAP
- Potential risks identified
- Investor confusion, market perception
AGP Limited (AGP) on Nafa
Last price Rs 155.97 · Pharmaceuticals · You can own AGP shares from your phone.
More AGP announcements
- NoticeFINAL REPORT ON THE PURCHASE / BUY-BACK OF SHARES BY AGP LIMITED
- NoticeTransmission of Quarterly Report for the Period Ended September 30, 2026
- Financial resultFinancial Results for the Quarter Ended September 30, 2026AGP Limited reported a decline in revenue to Rs 17.98 billion and net profit to Rs 2.59 billion for the nine months ended September 2026, indicating a challenging period with reduced profitability.
- NoticeBoard Meeting In Progress
- NoticeBOARD MEETING
- NoticeCOMPLETION OF PURCHASE PERIOD FOR BUY-BACK OF SHARES BY AGP LIMITED
Source: AGP Limited's filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.